Skip to main content
. 2021 Jul 22;20:15347354211031646. doi: 10.1177/15347354211031646

Figure 2.

Figure 2.

Huaier reduces the methylation levels of CDKN2A and TP53 by inhibiting DNMT1 expression in SCL-1 and A431 cells. SCL-1 cells were treated with 0, 4, 8, or 16 mg/mL of Huaier. (A) WB was performed to examine the expression of DNMT1, DNMT3A, and DNMT3B in SCL-1 cells. SCL-1 cells were transfected with LV-DNMT1 or LV-NC, and the modified SCL-1 cells were then treated with 8 mg/mL of Huaier. (B and C) MSP was performed to assess the methylation levels of CDKN2A and TP53 in the modified SCL-1 cells. (D-F) The gene and protein expression of CDKN2A and TP53 in modified SCL-1 cells were examined by qRT-PCR and WB. A431 cells were treated with 0, 4, 8, or 16 mg/mL of Huaier. (G) WB was performed to examine the expression of DNMT1, DNMT3A, and DNMT3B in A431 cells. A431 cells were transfected with LV-DNMT1 or LV-NC, and the modified A431 cells were then treated with 8 mg/mL of Huaier. (H and I) MSP was performed to assess the methylation levels of CDKN2A and TP53 in the modified A431 cells. (J-L) The gene and protein expression of CDKN2A and TP53 in modified A431 cells were examined by qRT-PCR and WB.

Abbreviations: M, methylation; U, unmethylation.

*P < .05, **P < .01, versus 0 mg/mL or control; #P < .05, versus 4 mg/mL; &P < .05, &&P < .01, versus 8 mg/mL or LV-NC.